Sultanate of Oman Ministry of Health Directorate General of Pharmaceutical Affairs and Drug Control Muscat



سلطنة عُـمان وزارة الـصحـة الـمـديـريـة الـعـامـة للـصيـدلـة والـرقـابـة الـدوائـيـة مسـةـط

To:

THE DIRECTOR GENERAL OF HEALTH SERVICES IN ALL GOVERNORATES

Commanding Officer, Armed Forces Hospital (Al Khoudh & Salalah)

Director General of Engineering Affairs, MOH

Director General of Royal Hospital

Director General of Khoula Hospital

Director General of Medical Supplies (MOH)

Director General of Pvt. Health Est. Affairs (to kindly arrange distribution to all Pvt. Hospitals)

Hospital Director (Al Nahda Hospital)

Hospital Director (Al Massara Hospital)

The Head of Medical Services in SQU Hospital

The Head of Medical Services in Royal Oman Police

The Head of Medical Services in Ministry of Defence

The Head of Medical Services in The Diwan

The Head of Medical Services in The Sultan's Special Force

The Head of Medical Services in Internal Security Services

The Head of Medical Services in Petroleum Development of Oman

The Head of Medical Services in LNG Oman

ALL PRIVATE PHARMACIES & DRUG STORES

After Compliments,

Please find attached our Circular No. 2.3....... dated 2.15.1.2.2... Regarding NCMDR FSCA of Alinity m SARS-CoV-2 AMP Kit, Alinity m Resp-4-Plex AMP Kit, Alinity m SARS-CoV-2 Application Specification File, and Alinity m Resp-4-Plex Application Specification File

from (mrf: Abbott Molecular Inc).

Copy to:

- Director, Office of H.E. The Undersecretary for Health Affairs
- Director of Medical Device Control, DGPA&DC
- Director of Pharmacovigilance & Drug Information Dept, DGPA&DC
- Director of Drug Control Department, DGPA&DC
- Director of Pharmaceutical Licensing Department, DGPA&DC
- Director of Central Quality Control Lab., DGPA&DC
- Supdt. of Central Drug Information





Sultanate of Oman Ministry of Health Directorate General of Pharmaceutical Affairs and Drug Control Muscat



وزارة الص

Circular No. \$3/2022 Formation

07 -**1443** H

08 -052022

Field Safety Corrective Action of Alinity m SARS-CoV-2 AMP Kit, Alinity m Resp-4-Plex AMP Kit, Alinity m SARS-Co

plication Specific	cation File, and Alinity m Resp-4-Plex Application Specification File. from Abbott Molecular Inc.
Source	NCMDR-National Center for Medical Device Reporting
	https://ncmdr.sfda.gov.sa/Secure/CA/CaViewRecall.aspx?caid=4&rid=16116
Product	Alinity m SARS-CoV-2 AMP Kit, Alinity m Resp-4-Plex AMP Kit, Alinity m SARS-CoV-2
	Application Specification File, and Alinity m Resp-4-Plex Application Specification File.
Description	IVD.
Manufacturer	Abbott Molecular Inc.
Local Agent	Waleed Pharmacy & Stores LLC.
The affected products	List Numbers: 09N78-090, 09N78-091, 09N79-090, 09N78-01E, and 09N79-01D Not Lot Specific. Unique Device Identifiers (UDIs): 00884999049215, 00884999049963, 00884999049338, (01)00884999050228(240)09N78-01E(8012)5.00, and (01)00884999050235(240)09N79-01D(8012)4.00
Reason	Reports of Alinity m SARS-CoV-2 false positive results.
Action	 Abbott has updated the existing Application Specification files for Alinity m SARS-CoV-2 and Resp-4-Plex to further reduce the potential for carryover. A Molecular Diagnostics Abbott Representative will be contacting you once the updated Application Specification files are available. Contact the local agent for remedial action.
Product Picture	Alinity m SARS-COV-2 AMP Kit For the quark another transport and another transport ano
comments	Healthcare professionals are encouraged to report any adverse events Suspected to be associated with the above device or any other medical device to Department of Medical Device Control contact E-mail:

Dr. Mohammed Hamdan Al Rubaie **DIRECTOR GENERAL**





Med-device@moh.gov.om



